Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Liabilities and Shareholders Equity (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $338.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 45.12% year-over-year to $338.0 million, compared with a TTM value of $1.8 billion through Dec 2025, up 71.63%, and an annual FY2025 reading of $338.0 million, down 45.12% over the prior year.
  • Liabilities and Shareholders Equity was $338.0 million for Q4 2025 at Keros Therapeutics, down from $742.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $757.2 million in Q2 2025 and bottomed at $230.0 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $384.7 million, with a median of $316.5 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity soared 325.35% in 2021, then tumbled 45.12% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $255.3 million in 2021, then increased by 20.19% to $306.8 million in 2022, then grew by 20.62% to $370.0 million in 2023, then soared by 66.44% to $615.9 million in 2024, then crashed by 45.12% to $338.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for KROS at $338.0 million in Q4 2025, $742.8 million in Q3 2025, and $757.2 million in Q2 2025.